Status
Recruiting
Phase
Not applicable
Enrollment
590
Locations
5
Results
Not posted
Publications
0
Study summary
This study aims to improve the early detection of undiagnosed heart disease, which causes serious health issues, hospital admissions, and high healthcare costs. Researchers are exploring how artificial intelligence (AI) can analyse routine heart tests, called electrocardiograms (ECGs), to detect heart problems. These tests can be done using both traditional ECG machines and portable, wearable devices like smartwatches, making it easier for people to monitor their heart health at home. While AI has shown promise using past data, this study will involve the collection of ECG data and subsequent testing of its accuracy in real-world settings to ensure it works well for both doctors and patients. The goal is to see if AI can identify conditions like heart muscle weakness, valve issues, and high lung pressure from the ECG data of patients. The researchers will also compare AI's detections with other blood tests commonly used to diagnose heart disease. The AI models that will be used are being tested for research and validation purposes only. They will not be used for clinical decision-making or providing information to influence diagnosis, treatment, or patient care during the study. The AI outputs are not shared with clinicians and will have no impact on the care pathway. This research will demonstrate if AI-powered ECG analysis - whether from traditional or portable devices - can provide a low-cost, non-invasive way to detect heart disease early and improve health assessments.
Interventions
OTHER
12-lead ECG investigation is a standard, non-invasive diagnostic procedure used as an intervention to assess participants' cardiac electrical activity. For the purposes of this study, 12-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
OTHER
Single-lead ECG taken using an Apple Watch Series 4 is a non-invasive, participant-initiated recording of cardiac electrical activity through a wearable device. While more limited than a 12-lead ECG, it can capture rhythm abnormalities-such as atrial fibrillation-and offers a convenient method for remote or continuous heart monitoring during the study. For the purposes of this study, single-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
OTHER
Three-lead ECG recorded using the Eko CORE 500 digital stethoscope is a non-invasive, clinician-operated cardiac assessment tool that captures real-time electrical activity of the heart during auscultation. It provides enhanced diagnostic information compared to single-lead recordings, allowing detection of arrhythmias and signs of structural heart disease at the point of care, supporting integrated clinical and digital assessment. For the purposes of this study, 3-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
OTHER
A single- or 6-lead ECG recorded using the AliveCor KardiaMobile 6L device which is a portable, non-invasive method for capturing cardiac electrical activity. Operated by the participant or clinician, the device enables rapid rhythm assessment and detection of abnormalities such as atrial fibrillation. The 6-lead configuration offers more comprehensive data than single-lead recordings, supporting enhanced arrhythmia and conduction analysis in both in-clinic and remote settings. For the purposes of this study, single- and 6-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
OTHER
A minimally invasive biomarker assessment used to evaluate cardiac wall stress and function. Elevated levels can indicate the presence or severity of heart failure and other forms of structural heart disease, making it a valuable tool for diagnosis, risk stratification, and monitoring of cardiac status throughout the study period. For the purposes of this study, NT-proBNP will be collected to assess its accuracy at detecting HF, PH, and VHD with comparison with AI-ECG detections. The investigators will also evaluate the accuracy of AI-ECG detections combined with NT-pro-BNP, for detecting HF, VHD, and PH. The investigators will not be using NT-proBNP results to inform or alter patients' standard NHS care.
Timeline
First posted
Jul 9, 2025
Study start
Nov 4, 2025
Primary completion
May 3, 2027
Study completion
Aug 2, 2027
Results posted
Not reported
Registry updated
Mar 9, 2026
Outcomes
AI-ECG model classification performance for detection of structural heart disease (SHD)
Time frame · From enrolment to end of patient's study visit (up to 1 hour)
AI-ECG model classification performance for HF, PH, and VHD, will be assessed for all ECG modalities (single-, 3-, 6-, and 12-lead ECGs) using the area under the receiver operating characteristic (AUROC; pre-defined threshold).
Additional AI-ECG performance metrics for detection of SHD
Time frame · From enrolment to end of patient's study visit (up to 1 hour)
Secondary performances measures will include sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and F1 score for all ECG modalities.
NT-proBNP performance metrics for detection of SHD
Time frame · From enrolment to end of patient's study visit (up to 1 hour)
performances measures will include area under the receiver operating characteristic (AUROC; pre-defined threshold), sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and F1 score for all ECG modalities.
Combined AI-ECG and NT-proBNP performance analysis for detection of SHD
Time frame · From enrolment to end of patient's study visit (up to 1 hour)
NT-proBNP and AI-ECG predictions will be combined in a logistic regression model to assess the performance of a combined approach.
Eligibility
Inclusion Criteria: * Patients aged 18-90 years * No prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD * Ability to provide informed consent Exclusion Criteria: * Severe arrhythmia or unstable cardiovascular disease * Prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD * Cardiac implantable electronic device in-situ, including a permanent pacemaker or implantable cardioverter defibrillator * Involvement in current research or recent involvement in any research prior to recruitment
Study locations
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
Southmead Hospital
Bristol, United Kingdom
Chelsea and Westminster Hospital
London, United Kingdom
Hammersmith Hospital
London, United Kingdom
St Mary's Hospital
London, United Kingdom
West Middlesex University Hospital
London, United Kingdom
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
Norfolk and Norwich University Hospitals NHS Foundation Trust · Vascular Surgical Procedure
Not applicable
Recruiting
200
2026-06
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.